Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Sooner Research

Neither a doctor nor a teaching hospital

Research payments

$1,571,168

351 payments

Through program year 2025, Central Sooner Research is reported as receiving $1,571,168 in research payments, across 351 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $251,175 62
2024 Research $194,130 48
2023 Research $163,832 65
2022 Research $172,682 44
2021 Research $196,210 47
2020 Research $312,908 43
2019 Research $280,231 42

Breakdown

Who paid Research payments · program years 2019–2025
  1. Incyte Corporation $604,518 184 payments
  2. Ucb SA $327,072 59 payments
  3. E.R. Squibb & Sons, L.L.C. $131,674 5 payments
  4. Eli Lilly and Company $108,050 15 payments
  5. Celgene Corporation $100,050 9 payments
  6. Ironwood Pharmaceuticals, Inc $61,628 10 payments
  7. Regeneron Pharmaceuticals, Inc. $54,971 14 payments
  8. AstraZeneca UK Limited $51,144 13 payments
  9. Genentech, Inc. $31,702 11 payments
  10. Allergan Inc. $30,094 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant, Investigator, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of Ucb1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) $226,826 54 payments
  2. A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of Ucb1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) $100,246 5 payments
  3. TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $94,669 13 payments
  4. TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $74,037 14 payments
  5. A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus $71,632 11 payments
  6. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to $71,058 1 payment
  7. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 1) $66,865 4 payments
  8. Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo $66,314 19 payments
  9. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo $64,226 12 payments
  10. A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma $62,995 10 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $45 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record